Literature DB >> 14522091

High frequency of HLA-B44 allelic losses in human solid tumors.

Teresa Cabrera1, Isabel Maleno, Miguel Angel Lopez-Nevot, Maximino Redondo, Maria Angustias Fernandez, Antonia Collado, Federico Garrido.   

Abstract

Human leukocyte antigen (HLA) class I downregulation, a frequent phenomenon observed in a variety of human tumors, favors tumor immune escape from T-lymphocyte recognition. However, it is not known whether a particular HLA class I allele is lost more frequently than others. To address this question we analyzed HLA class I expression in tumor tissues derived from 300 patients diagnosed as having breast, colorectal, or laryngeal carcinomas. Cryostatic tumor sections and a broad panel of anti-HLA class I monoclonal antibodies were used. We found that the HLA-B44 allele was lost more frequently than other HLA class I alleles, and that the difference was not related with changes in HLA-B44 allele frequencies between patients and controls. In addition, we observed that 35% of the HLA-B44 negative tumors presented HLA haplotype loss associated with loss of heterozygosity. These tests were performed on DNA samples obtained from microdissected tumor tissues. The results seem to indicate that HLA class I allelic losses are not randomly distributed during tumor development but that some HLA class I alleles, and HLA-B44 in particular, are more frequently downregulated and may play an important role in immune escape mechanisms.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14522091     DOI: 10.1016/s0198-8859(03)00164-2

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  4 in total

1.  Prediction of lymph node metastasis by analysis of gene expression profiles in primary lung adenocarcinomas.

Authors:  Liqiang Xi; James Lyons-Weiler; Michael C Coello; Xin Huang; William E Gooding; James D Luketich; Tony E Godfrey
Journal:  Clin Cancer Res       Date:  2005-06-01       Impact factor: 12.531

2.  MHC class II molecules on pancreatic cancer cells indicate a potential for neo-antigen-based immunotherapy.

Authors:  Renato B Baleeiro; Christian J Bouwens; Peng Liu; Carmela Di Gioia; Louisa S Chard Dunmall; Ai Nagano; Rathistevy Gangeswaran; Claude Chelala; Hemant M Kocher; Nicholas R Lemoine; Yaohe Wang
Journal:  Oncoimmunology       Date:  2022-05-27       Impact factor: 7.723

3.  Role of the inhibitory KIR ligand HLA-Bw4 and HLA-C expression levels in the recognition of leukemic cells by Natural Killer cells.

Authors:  Sonja Verheyden; Soldano Ferrone; Arend Mulder; Frans H Claas; Rik Schots; Barbara De Moerloose; Yves Benoit; Christian Demanet
Journal:  Cancer Immunol Immunother       Date:  2008-10-08       Impact factor: 6.968

4.  Loss of the mismatched human leukocyte antigen haplotype in two acute myelogenous leukemia relapses after haploidentical bone marrow transplantation with post-transplantation cyclophosphamide.

Authors:  S R McCurdy; B S Iglehart; D A Batista; C D Gocke; Y Ning; H A Knaus; A M Jackson; M S Leffell; L Luznik; I Gojo
Journal:  Leukemia       Date:  2016-05-23       Impact factor: 11.528

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.